Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging Evaluation of [11C]SY08
NCT06098612Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2024
- Primary completion
- Nov 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [11C]SY08 in Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB), sponsored by Massachusetts General Hospital. Primary endpoint: Brain uptake evaluation at 120 months. Started May 2024; status: recruiting.
02
Drugs
[11C]SY08
03
Conditions
Parkinson's disease (PD)multiple system atrophy (MSA)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT06098612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098612.